Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference.

Novavax (NasdaqGS:NVAX) recently amended its collaboration agreement with Takeda, enhancing its revenue potential through a new upfront payment structure and future royalties. These developments, ...

We expect Novavax NVAX to surpass expectations when it reports first-quarter 2025 earnings on May 8, before the opening bell.

Novavax Inc. closed 73.72% short of its 52-week high of $23.86, which the company achieved on June 6th.

Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might ...

The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine ...

Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after previously ...

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

Novavax, Inc. (NVAX) said it has updated the terms of the collaboration and licensing agreement with Takeda. The company noted that the improved financial terms of the amended ...

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

In the most recent trading session, Novavax (NVAX) closed at $6.41, indicating no shift from the previous trading day. ANI (ANIP) possesses the right combination of the two key ingredients for a ...

Novavax Inc. closed 73.09% below its 52-week high of $23.86, which the company achieved on June 6th.